Volemia in Dialysis Patients
Conditions
Brief summary
A precise volume status assessment is critical to improve outcome of patients on dialysis. Yet, accurate assessment of fluid status remains a challenge. Currently, this is performed by clinical evaluation and regular weight measurements before and after dialysis, which is not always accurate. Moreover, bioimpedance technology is used in some centers for quantitative assessment of total body water. This approach has been validated for the assessment of volume status in dialysis patients, but requires the acquisition of specific tools and is time consuming. So far, no biomarker has been validated to quantify volume status in dialysis patients. Application of biomarkers might contribute to a better dialysis prescription and therefore to outcome improvement in dialysis. The investigators aim to investigate the role of a novel biomarkers (sCD146) to assess volume status in dialysis patients
Interventions
DEVICEbioelectrical impedance measurement and biomarker measurement
Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
University of Zurich
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years old * Patient on dialysis since \> 1 month * Voluntarily signed informed consent
Exclusion criteria
* Pregnant or breastfeeding women and women who plan to get pregnant during study * Incapability of following the study protocol * Acute illness * Hospitalizations in the last week before inclusion * Cardiac pacemakers or defibrillators * Limb amputation or other factors precluding a reliable bioimpedance measurement (unreliable bioimpedance measurement)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of sCD146 level with overhydration assessed by bioimpedance technology | 3 weeks to 3 months | For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of sCD146 level and clinical evaluation of volume status | 3 weeks to 3 months | For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months |
| Correlation of sCD146 level and level of NT-proBNP | 3 weeks to 3 months | For hemodialysis patients measurements will be concluded within 3 weeks, for peritoneal dialysis patients measures will be concluded within 3 months |
| Correlation of sCD146 level and mortality as assessed prospectively in 6 months follow-up | 6 months | — |
| Correlation of sCD146 level measured after dialysis and ultrafiltration rate | 3 weeks | for hemodialysis patients measurements will be concluded within 3 weeks |
| Correlation of sCD146 level and cardiovascular complications as assessed prospectively in 6 months follow-up | 6 months | — |
| Correlation of sCD146 level and shunt complications as assessed prospectively in 6 months follow-up | 6 months | — |
| Correlation of sCD146 level and hospitalizations as assessed prospectively in 6 months follow-up | 6 months | — |
Countries
Switzerland
Outcome results
None listed